Drug Shortage Report for ADENOSINE INJECTION
Report ID | 222725 |
Drug Identification Number | 02457482 |
Brand name | ADENOSINE INJECTION |
Common or Proper name | ADENOSINE INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | ADENOSINE |
Strength(s) | 3MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 4 mL |
ATC code | C01EB |
ATC description | OTHER CARDIAC PREPARATIONS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2024-03-31 |
Actual start date | |
Estimated end date | 2024-05-15 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2024-04-01 |
Company comments | Fresenius Kabi Canada regrets to advise that due to increase demand, we will be encountering a supply interruption on our Adenosine Injection 3 mg/mL Prefilled syringe 4 mL effective March 31, 2024, until May 15, 2024. During this time, our Adenosine Injection 3 mg/mL Prefilled syringe 2 mL will be available for substitution. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2024-04-01 | English | Compare |
v2 | 2024-03-19 | French | Compare |
v1 | 2024-03-19 | English | Compare |
Showing 1 to 3 of 3